HIV: TAF inc weight /metabolic changes
A recent Swiss cohort study confirmed prior studies finding increased weight gain and lipid changes with tenofovir alafenamide (TAF); this study assessed changes after having been switched from tenofovir disoproxil fumarate, TDF, to TAF (see hiv TAF inc wt metab change AIM2021 in dropbox, or doi:10.7326/M20-4853 ) Details: -- 4375 adults living with HIV who had been on TDF-containing regimens for 6 months or longer, comparing pre-vs post-switch to TAF vs those remaining on TDF, after 18 months. From January 2016 to August 2019 -- 5 University hospitals, affiliated hospitals, and private physicians in Switzerland participated -- median age 50, 26% female, 51% normal BMI, median CD4 count 650, median duration of ART 11 years, mean duration of TDF before the index visit 8 years, -- medical comorbidities: diabetes 5%, history of vascular disease 6%, smoker 37%, lipid-lowering therapy 15%, median weight 74 kg, median BMI 24, median HDL 50 mg/dL , m...